肺腺癌表皮生长因子受体基因突变与血清肿瘤标志物的关系  

Relationship of EGFR Mutations with Serum Tumor Markers in Lung Adenocarcinoma

作　　者：鄢丽敏 张志勇[1] 闫继东[2] 刘丽云[1] 夏庆安[1] 崔永兴[1] YAN Limin;ZHANG Zhiyong;YAN Jidong;LUU Liyun;XIA Qingan;CUI Yongxing(Department of Pathology, Tangshan Worker Hospital, Tangshan 063000, Chin)

机构地区：[1]唐山市工人医院病理科,河北唐山063000 [2]唐山市工人医院胸外科,河北唐山063000

出　　处：《实用医学杂志》2018年第7期1056-1058,1063,共4页The Journal of Practical Medicine

基　　金：河北省科技计划自筹经费项目(编号:162777167);河北省医学科学研究课题计划项目(编号:20171380)

摘　　要：目的分析EGFR基因突变与血清癌胚抗原(CEA)、甲胎蛋白(AFP)、神经元特异性烯醇化酶(NSE)、糖类抗原(CA19-9)水平之间的关系。从而为肺腺癌患者行EGFR基因检测及相应靶向治疗提供相对优势人群。方法收集2015年8月至2017年7月于河北省唐山市工人医院病理科行EGFR基因突变检测的肺腺癌患者。采用突变扩增阻滞系统(ARMS)方法对EGFR基因的18至21号外显子的41个位点进行检测,采用电化学发光免疫法检测血清CEA、AFP、NSE、CA19-9水平。结果 EGFR基因突变率与患者血清肿瘤标志物CEA水平有关(χ~2=7.207,P=0.007),随着血清CEA水平的升高,EGFR基因突变率呈现上升趋势(χ~2=12.428,P=0.006)。结论血清CEA水平增高的肺腺癌患者是EGFR基因检测的优势人群。Objective To identify the relationship of epidermal growth factor receptor （EGFR） mutations and serum tumor markers such as carcinoembryonic antigen （CEA）, alpha fetal protein （AFP）, neuron specific enolase （NSE）, carbohydrate antigen 199 （CA19-9） , and to optimize the identification of patients who should undergo EGFR mutation testing. Methods We retrospectively reviewed the data of lung adenocarcinoma patients who underwent EGFR gene mutation testing between May 2015 and April 2017. These samples were detected EGFR mutations of gene exon 18 to 21 and serum tumor markers, by amplification refractory mutation system （ARMS） and electrochemiluminescence immunoassay. Results EGFR mutations were significantly associated with serum CEA level （X2 = 7.207, P = 0.007）, and with the increase of serum CEA level, the mutation rate of EGFR gene showed an upward trend （X2 = 12.428, P = 0.006）. Conclusion Lung adenocarcinoma patients with elevated serum CEA levels should be the dominant group for EGFR gene testing.

关 键 词：肺腺癌 表皮生长因子受体 突变 癌胚抗原 

分 类 号：R734.2[医药卫生—肿瘤]